Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...

Artificial-intelligence software is being used to re-create Moshe Nussbaum's widely recognized, distinctive voice ...

A New Bedford man was sentenced to prison for conspiring to steal and then depositing over $450,000 from a U.S. Marine ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

company is now working on screening, enrollment and dosing for a Phase 1 trial of AMX0114, a drug for people living with ALS--amyotrophic lateral sclerosis--a fatal disease that triggers ...